10 completed, 7 terminated, 1 active not recruiting. 10 Phase 3, 7 Phase 1, 4 Phase 2.
By phase and status
Follow gantenerumab: new trials by email Literature Review of gantenerumab trials Research Report on gantenerumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) Gantenerumab, Placebo - Alzheimers Disease Phase 3 Terminated 25 2022-04-19 2025-06-12 A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) Gantenerumab - Alzheimer Disease Phase 3 Terminated 1382 2021-01-26 2024-05-08 A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Gantenerumab - Alzheimer Disease Phase 2 Terminated 192 2020-11-18 2024-03-27 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation Gantenerumab - Alzheimers Disease, Dementia Phase 2 / Phase 3 Terminated 73 2020-06-03 2025-02-04 A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD) Gantenerumab - Alzheimer Disease Phase 3 Terminated 116 2020-05-22 2024-01-18 Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Gantenerumab, Placebo - Alzheimer Disease Phase 3 Terminated 975 2018-08-22 2024-01-17 Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Gantenerumab, Placebo - Alzheimer Disease Phase 3 Terminated 1053 2018-06-06 2024-01-30 Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants Gantenerumab - Healthy Participants Phase 1 Completed 114 2017-08-01 2018-12-12 A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants Gantenerumab, Placebo - Healthy Volunteer Phase 1 Completed 48 2016-08-31 2019-06-11 A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers Gantenerumab, Placebo - Healthy Volunteer Phase 1 Completed 18 2016-03-31 2019-04-10 A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers gantenerumab - Healthy Volunteer Phase 1 Completed 31 2014-04-01 2016-11-02 A Study of Gantenerumab in Participants With Mild Alzheimer Disease Placebo, Gantenerumab - Alzheimer's Disease Phase 3 Completed 389 2014-03-27 2023-02-10 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab) - Alzheimers Disease, Dementia Phase 2 / Phase 3 Active not recruiting 490 2012-12-01 2026-07-27 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab) - Alzheimers Disease, Dementia Phase 2 / Phase 3 Completed 194 2012-12-01 2022-09-22 A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients Gantenerumab, Placebo - Alzheimer's Disease Phase 1 Completed 28 2012-06-01 2014-09-19 A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers gantenerumab - Healthy Volunteer Phase 1 Completed 120 2012-05-01 2016-11-02 A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease Gantenerumab, Placebo - Alzheimer's Disease Phase 3 Completed 799 2010-11-30 2021-12-13 A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease. gantenerumab - Alzheimer's Disease Phase 1 Completed 60 2006-12-01 2016-11-02
Conditions studied Alzheimer Disease (13) · Dementia (3)
Sponsors Hoffmann-La Roche (14) · Washington University School of Medicine (3) · Chugai Pharmaceutical (1)
Countries United States (15) · Spain (11) · United Kingdom (11) · Australia (9) · France (9) · Canada (8) · Italy (8) · Argentina (7) · Japan (7) · Netherlands (7) · Denmark (6) · Germany (6) · Poland (6) · South Korea (6) · Sweden (6)
Top investigators Randall J Bateman, MD (3)
Results publications PMID 39556389 , PMID 31831056 , PMID 37966285 , PMID 39177596 , PMID 39887500 , PMID 39974075 , PMID 40120616 , PMID 40302041 , PMID 40603145 , PMID 42598748 , PMID 22583155 , PMID 29221491 , PMID 31883703 , PMID 36110925 , PMID 37017737 , PMID 38683602 , PMID 39686620 , PMID 40985290 , PMID 41085131 , PMID 41537338
NIH funding R01AG046179 (3) , U01AG042791 (3) , 2017 (2) , R01AG053267 (2) , R56AG053267 (2) , U01AG059798 (2) , 2015 (1)